New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%

A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62% after a single infusion in an early trial, raising hopes for a long-lasting treatment to reduce heart attack risk